154 related articles for article (PubMed ID: 21531819)
61. Co-evolution of somatic variation in primary and metastatic colorectal cancer may expand biopsy indications in the molecular era.
Kim R; Schell MJ; Teer JK; Greenawalt DM; Yang M; Yeatman TJ
PLoS One; 2015; 10(5):e0126670. PubMed ID: 25974029
[TBL] [Abstract][Full Text] [Related]
62. Interactions of multiple gene alterations in colorectal liver metastases.
Kawaguchi Y; Velasco JD; Arvide EM; Wei SH; Vauthey JN
Chin Clin Oncol; 2019 Oct; 8(5):50. PubMed ID: 31500427
[TBL] [Abstract][Full Text] [Related]
63. RAS Mutation Clinical Risk Score to Predict Survival After Resection of Colorectal Liver Metastases.
Brudvik KW; Jones RP; Giuliante F; Shindoh J; Passot G; Chung MH; Song J; Li L; Dagenborg VJ; Fretland ÅA; Røsok B; De Rose AM; Ardito F; Edwin B; Panettieri E; Larocca LM; Yamashita S; Conrad C; Aloia TA; Poston GJ; Bjørnbeth BA; Vauthey JN
Ann Surg; 2019 Jan; 269(1):120-126. PubMed ID: 28549012
[TBL] [Abstract][Full Text] [Related]
64. Can KRAS and BRAF mutations limit the benefit of liver resection in metastatic colorectal cancer patients? A systematic review and meta-analysis.
Passiglia F; Bronte G; Bazan V; Galvano A; Vincenzi B; Russo A
Crit Rev Oncol Hematol; 2016 Mar; 99():150-7. PubMed ID: 26775732
[TBL] [Abstract][Full Text] [Related]
65. FOLFOX4 Plus Cetuximab for Patients With Previously Untreated Metastatic Colorectal Cancer According to Tumor RAS and BRAF Mutation Status: Updated Analysis of the CECOG/CORE 1.2.002 Study.
Kaczirek K; Ciuleanu TE; Vrbanec D; Marton E; Messinger D; Liegl-Atzwanger B; Wrba F; Knittelfelder R; Lindner E; Zielinski CC; Streubel B; Brodowicz T
Clin Colorectal Cancer; 2015 Jun; 14(2):91-8. PubMed ID: 25666295
[TBL] [Abstract][Full Text] [Related]
66. Genetic And Morphological Evaluation (GAME) score for patients with colorectal liver metastases.
Margonis GA; Sasaki K; Gholami S; Kim Y; Andreatos N; Rezaee N; Deshwar A; Buettner S; Allen PJ; Kingham TP; Pawlik TM; He J; Cameron JL; Jarnagin WR; Wolfgang CL; D'Angelica MI; Weiss MJ
Br J Surg; 2018 Aug; 105(9):1210-1220. PubMed ID: 29691844
[TBL] [Abstract][Full Text] [Related]
67. The role of cetuximab as first-line treatment of colorectal liver metastases.
Jones C; Taylor MA; McWilliams B
HPB (Oxford); 2013 Jan; 15(1):11-7. PubMed ID: 23216774
[TBL] [Abstract][Full Text] [Related]
68. The effects of resection margin and KRAS status on outcomes after resection of colorectal liver metastases.
Hatta AAZ; Pathanki AM; Hodson J; Sutcliffe RP; Marudanayagam R; Roberts KJ; Chatzizacharias N; Isaac J; Muiesan P; Taniere P; Mirza DF; Dasari BVM
HPB (Oxford); 2021 Jan; 23(1):90-98. PubMed ID: 32417170
[TBL] [Abstract][Full Text] [Related]
69. A combined oncogenic pathway signature of BRAF, KRAS and PI3KCA mutation improves colorectal cancer classification and cetuximab treatment prediction.
Tian S; Simon I; Moreno V; Roepman P; Tabernero J; Snel M; van't Veer L; Salazar R; Bernards R; Capella G
Gut; 2013 Apr; 62(4):540-9. PubMed ID: 22798500
[TBL] [Abstract][Full Text] [Related]
70. Genomic stratification beyond Ras/B-Raf in colorectal liver metastasis patients treated with hepatic arterial infusion.
Smith JJ; Chatila WK; Sanchez-Vega F; Datta J; Connell LC; Szeglin BC; Basunia A; Boucher TM; Hauser H; Wasserman I; Wu C; Cercek A; Hechtman JF; Madden C; Jarnagin WR; Garcia-Aguilar J; D'Angelica MI; Yaeger R; Schultz N; Kemeny NE
Cancer Med; 2019 Nov; 8(15):6538-6548. PubMed ID: 31503397
[TBL] [Abstract][Full Text] [Related]
71. Analysis of KRAS, NRAS, BRAF, and PIK3CA mutations could predict metastases in colorectal cancer: A preliminary study.
Wojas-Krawczyk K; Kalinka-Warzocha E; Reszka K; Nicoś M; Szumiło J; Mańdziuk S; Szczepaniak K; Kupnicka D; Lewandowski R; Milanowski J; Krawczyk P
Adv Clin Exp Med; 2019 Jan; 28(1):67-73. PubMed ID: 30085422
[TBL] [Abstract][Full Text] [Related]
72. RNAi screening of the human colorectal cancer genome identifies multifunctional tumor suppressors regulating epithelial cell invasion.
Ly P; Eskiocak U; Parker CR; Harris KJ; Wright WE; Shay JW
Cell Res; 2012 Nov; 22(11):1605-8. PubMed ID: 23044803
[No Abstract] [Full Text] [Related]
73. KRAS mutation in patients undergoing hepatic resection for colorectal liver metastasis: a biomarker of cancer biology or a byproduct of patient selection?
Søreide K; Sandvik OM; Søreide JA
Cancer; 2014 Dec; 120(24):3862-5. PubMed ID: 25155780
[No Abstract] [Full Text] [Related]
74. Does RAS Status Increase the Prevalence of Positive Resection Margin in Colorectal Liver Metastasis? A Systematic Review and Meta-Analysis.
Brandão GR; Trindade BO; Flores LHF; Motter SB; Alves CB; Remonti TAP; Lucchese AM; Junior ADP; Kalil AN
Am Surg; 2023 Dec; 89(12):5638-5647. PubMed ID: 36896840
[TBL] [Abstract][Full Text] [Related]
75. A caution against KRAS-guided margin width during hepatectomy for colorectal liver metastases.
Haddad A; Vauthey JN; Newhook TE
Surgery; 2024 Jul; 176(1):134-136. PubMed ID: 38632003
[No Abstract] [Full Text] [Related]
76. Safety and utility of image-guided research biopsies in relapsed high-grade serous ovarian carcinoma-experience of the BriTROC consortium.
Goranova T; Ennis D; Piskorz AM; Macintyre G; Lewsley LA; Stobo J; Wilson C; Kay D; Glasspool RM; Lockley M; Brockbank E; Montes A; Walther A; Sundar S; Edmondson R; Hall GD; Clamp A; Gourley C; Hall M; Fotopoulou C; Gabra H; Freeman S; Moore L; Jimenez-Linan M; Paul J; Brenton JD; McNeish IA
Br J Cancer; 2017 May; 116(10):1294-1301. PubMed ID: 28359078
[TBL] [Abstract][Full Text] [Related]
77. Chromothripsis is a common mechanism driving genomic rearrangements in primary and metastatic colorectal cancer.
Kloosterman WP; Hoogstraat M; Paling O; Tavakoli-Yaraki M; Renkens I; Vermaat JS; van Roosmalen MJ; van Lieshout S; Nijman IJ; Roessingh W; van 't Slot R; van de Belt J; Guryev V; Koudijs M; Voest E; Cuppen E
Genome Biol; 2011 Oct; 12(10):R103. PubMed ID: 22014273
[TBL] [Abstract][Full Text] [Related]
78. BEAMing up personalized medicine: mutation detection in blood.
Richardson AL; Iglehart JD
Clin Cancer Res; 2012 Jun; 18(12):3209-11. PubMed ID: 22550168
[TBL] [Abstract][Full Text] [Related]
79. Comment on "RAS/TP53 co-Mutation is Associated With Worse Survival After Concurrent Resection of Colorectal Liver Metastases and Extrahepatic Disease".
Wang J; Andreatos N; Margonis GA
Ann Surg; 2021 Dec; 274(6):e935-e936. PubMed ID: 34334649
[No Abstract] [Full Text] [Related]
80. [Artificial intelligence for determining the optimal tumor-free resection margin in colorectal liver metastases].
Roth S; Schneider M
Chirurgie (Heidelb); 2022 Aug; 93(8):811-812. PubMed ID: 35789279
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
